Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

First International Summit on Interventional Pharmacoeconomics

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Peter Clark, MA, MD, FRCP: A Payer Perspective

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Opening Session Panel Discussion

May

Today In Oncology

Risk of Arterial Thromboembolism in Japanese Patients With Cancer

Breast Implant–Related Cancers: Should Our Patients Be Concerned?

Metastatic Urothelial Cancer NECTIN4 Amplification and Response to Enfortumab Vedotin

Salvage Reirradiation for Locally Recurrent Prostate Cancer 7-Year Follow-up

Effect of Mindfulness Audio Recordings on Physical Emotional Side Effects During Radiation Therapy for Prostate Cancer

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Related Videos